Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Chen WQ, Zeng HM, Zheng RS, Zhang SW, He J. Cancer incidence and mortality in china, 2007. Chin J Cancer Res 2012; 24:1-8; PMID:23359628; http://dx.doi.org/10.1007/s11670-012-0001-6
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nordlinger B Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010; 21 Suppl 5:v93-7; http://dx.doi.org/10.1093/annonc/mdq222
   PubMed Web of Science ®Google Scholar
• Kievit J. Follow-up of patients with colorectal cancer: numbers needed to test and treat. Eur J Cancer 2002; 38:986-99; PMID:11978524; http://dx.doi.org/10.1016/S0959-8049(02)00061-8
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al. FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:1065-75; PMID:25088940; http://dx.doi.org/10.1016/S1470-2045(14)70330-4
   PubMed Web of Science ®Google Scholar
• Ciardiello F LHJ, Köhne CH. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol 2014:32:5s, (suppl; abstr 3506) 2014; http://meetinglibrary.asco.org/content/127862-144.
   Google Scholar
• Bokemeyer C KCH, Ciardiello F. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol 2014;32:5s, (suppl; abstr 3505) 2014; http://meetinglibrary.asco.org/content/127861-144.
   Google Scholar
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000558/WC500029119.pdf. Accessed November, 24, 2014
   Google Scholar
• https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed November, 24, 2014
   Google Scholar
• Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, Iacovelli R, Miceli R, Bossi I, Leone G, et al. Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PLoS One 2014; 9:e92147; PMID:24691006; http://dx.doi.org/10.1371/journal.pone.0092147
   PubMedGoogle Scholar
• Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, von der Schulenburg JM. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer 2014; 50:40-9; PMID:24011538; http://dx.doi.org/10.1016/j.ejca.2013.08.008
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14:29-37; PMID:23168366; http://dx.doi.org/10.1016/S1470-2045(12)70477-1
   PubMed Web of Science ®Google Scholar
• Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010; 32:437-53; PMID:20399983; http://dx.doi.org/10.1016/j.clinthera.2010.03.012
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32:2240-7; PMID:24687833; http://dx.doi.org/10.1200/JCO.2013.53.2473
   PubMed Web of Science ®Google Scholar
• Alan P. Venook DN H-JL, Innocenti F, Mahoney MR, Bert H. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014; 32:5s, (suppl; abstr LBA3) 2014; http://dx.doi.org/10.1200/JCO.2013.49.4757
   Google Scholar
• Stintzing AJ S, Rossius L, Modest DP, Fischer von Weikersthal L, Decker T, Möhler M, Scheithauer W, Kirchner T, Heinemann V. LATE BREAKING ABSTRACT: Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. European Cancer Congress 2013 2013; Abs:17
   Google Scholar
• Carsten Bokemeyer CHK, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, Tejpar S. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. ASCO Annual Meeting Abstract 3505 Presented June 2, 2014 2014
   Google Scholar
• Fortunato Ciardiello HJL, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, Van Cutsem E. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. ASCO Annual Meeting Abstract 3506 Presented June 2, 2014 2014
   Google Scholar
• Douillard JY, Rong A, Sidhu R. RAS mutations in colorectal cancer. N Engl J Med 2013; 369:2159-60; PMID:24283232; http://dx.doi.org/10.1056/NEJMoa1305275
   PubMed Web of Science ®Google Scholar
• Graham CN, Hechmati G, Hjelmgren J, de Liege F, Lanier J, Knox H, Barber B. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 2014; 50:2791-801; PMID:25219451; http://dx.doi.org/10.1016/j.ejca.2014.08.016
   PubMed Web of Science ®Google Scholar
• Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 2011; 17:6338-46; PMID:21807639; http://dx.doi.org/10.1158/1078-0432.CCR-10-2267
   PubMed Web of Science ®Google Scholar
• Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 2012; 104:1785-95; PMID:23197490; http://dx.doi.org/10.1093/jnci/djs433
   PubMed Web of Science ®Google Scholar
• Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). J Med Econ 2013; 16:1387-98; PMID:24102083; http://dx.doi.org/10.3111/13696998.2013.852097
   PubMedGoogle Scholar
• Deborah Schrag ACD, Naughton MJ, Niedzwiecki D, Earle C, Shaw JD, Grothey A, Hochster HS, Blanke CD, Venook AP. Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. J Clin Oncol 2015; 33(suppl; abstr 6504):2015; PMID:26101248
   PubMed Web of Science ®Google Scholar
• Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu-Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther 2008; 30:382-92; PMID:18343276; http://dx.doi.org/10.1016/j.clinthera.2008.02.013
   PubMed Web of Science ®Google Scholar
• Petrou PK, Talias MA. Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus. Expert Rev Pharmacoecon Outcomes Res 2014; 14:131-8; PMID:24397606; http://dx.doi.org/10.1586/14737167.2014.873703
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Messonnier ML. Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale. Health Econ 2004; 13:21-35; PMID:14724891; http://dx.doi.org/10.1002/hec.793
   PubMed Web of Science ®Google Scholar
• Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000; 9:235-51; PMID:10790702; http://dx.doi.org/10.1002/(SICI)1099-1050(200004)9:3%3c235::AID-HEC502%3e3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7:518-28; PMID:15367247; http://dx.doi.org/10.1111/j.1524-4733.2004.75003.x
   PubMed Web of Science ®Google Scholar